MENG Linghua
Principal Investigator
Cancer Research Center
Personal Homepage
CONTACT
lhmeng@simm.ac.cn
021-50801669
201203
501 Haike Rd. Shanghai
Biography
Dr. Ling-hua Meng’s research focuses on discovery and research on innovative anticancer drugs targeting PI3K/mTOR pathway and tumor immunology as well as therapeutic strategy based on newly developed anticancer drug candidates. She has published more than 90 research articles in SCI-cited journals including prestigious international journals in tumor pharmacology and oncology, such as Cancer Res, Trends in Pharmacol Sci, Oncogene, Nucleic Acids Res and hold 37 domestic or international patents. She was granted with 10 domestic and international academic awards including National Natural Science Award (second degree, 2009), Shanghai Science & Technology Award (first degree, 2008), Servier Young Investigator in Pharmacology (2008), AACR-Scholar-in-Training Award (2004, 2005).
EDUCATION
1996.9-2001.7: Ph.D in Pharmacology Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
1992.9-1996.6: B.S in Biology; East China Normal University; Shanghai, China
WORK EXPERIENCE
2008.11 – present Professor, Division of Antitumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
2006.3 – 2008.10 Associate Professor, Division of Antitumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
2001.7-2006.3 Postdoctoral research Fellow; Laboratory of Molecular Pharmacology, National Cancer Institute
Research Directions
Grants & Research Projects
1)2008、2012、2014、2018、2020、2022, National Natural Sciences fund
2)2017、 2019, Strategic Priority Research Program of the Chinese Academy of Sciences
3)2008、2019, National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”
4)2008、2014, Science and technology commission of Shanghai Municipality
5)2008-2016, key personnel, Innovative research group of National Natural Sciences fund
6)2008,, Pujiang Talent Program, Science and technology commission of Shanghai Municipality
Achievements
1.Published more than 90 research articles in SCI-cited journals
2.Hold 37 domestic or international patents
3.Three anti-cancer drug candidates entered clinical trials
morefold
Social Titles
morefold
Awards & Honors
1.Wuxi AppTec Life Science and Chemistry award, 2013
2.7th Innovative Award for women Scientists in Shanghai, 2012
3.Meiji Biological Science award, 2011
4.Sanofi-Aventis-SIBS Young Faculty Award，2010
5.Second prize of the National Natural Science Award, 2009
6.Servier Young Investigator in Pharmacology, 2008
7.First prize of the Natural Science Award (Shanghai municipality), 2007
8.First prize of Shanghai Pharmaceutical Science,2005
9.AACR-Eli Lily Scholar-in-training Award in 2005
10.AACR-AstraZeneca Scholar-in-Training Award in 2004
morefold
Pubilcations
Full Publication List
Selected Publications
1.Xing H, Gao MS, Wang YX, Zhang X, Shi J, Wang X, Liu X, Ma Q, Kong X, Yang C, Ding J*, Meng L*. Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in esophageal squamous cell carcinoma. Clin Transl Med. 2022;12:e835
2.Zhang X, Wang YX, Meng L*. Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy. Acta Pharmaceutica Sinica B. 2022; 12( 3): 1054-1067
3.Chen ZQ, Cao ZR, Wang Y, Zhang X, Xu L, Wang YX, Chen Y, Yang CH, Ding J*, Meng LH*. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma. Cancer Lett. 2022 ;524:206-218.
4.Sun P, Zhang X, Wang RJ, Ma QY, Xu L, Wang Y, Liao HP, Wang HL, Hu LD, Kong X*, Ding J*, Meng LH*. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8 + T cells and promoting fatty acid metabolism. J Immunother Cancer. 2021; 9(8):e003093.
5.Wang YX, Zhang X, Ma QY, Hu LD, Zhang X, Wang Y, Xu L, Yang CH, Tan C, Kong XY, Ding J*, Meng LH*. Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cell. Cell Death Dis. 2021;12(1):85.
6.Liu XL, Wang BB, Wang Y, Wang YX, Yang CH, Tan C, Zhang X, He QJ, Ding J*, Meng LH*. Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3Kα inhibition in breast cancer. Signal Transduct Target Ther. 2019 Nov 22;4:49.
7.Shi JJ, Xing H, Wang YX , Zhang X, Zhan QM, Geng MY, Ding J*, Meng LH*. PI3Kα Inhibitors Sensitize Esophageal Squamous Cell Carcinoma to Radiation by Abrogating Survival Signals in Tumor Cells and Tumor Microenvironment. Cancer Lett. 2019;459:145-155
8.Liu XL, Liu JL, Xu YC, Zhang X, Wang YX, Qing LH, Guo W, Ding J*, Meng LH*. Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CAH1047R accompanied with pro-tumorigenic secretome. Int J Cancer. 2019; 145:817-829
9.Liu XL, Xu YC, Wang YX, Chen Y, Wang BB, Wang Y, Hu LD, Ma QY, Zhang YC, Sun YM, Gao YL, Yang CH, Ding J*, Meng LH*. Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer. Cancer Lett. 2018;433:273-282.
10.Xu YC, Wang X, Chen Y, Chen SM, Yang XY, Sun YM, Geng MY, Ding J*, Meng LH*. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Ka-selective Inhibitors in Breast Cancer. Theranostics 2017; 7:974-986
morefold
Back